RNA Interference Therapeutics Market Size & Share 2026-2035

RNA Interference Therapeutics Market Size

The global RNA interference therapeutics market was valued at USD 4.2 billion in 2025 and is projected to reach USD 31.4 billion by 2035, expanding at a CAGR of 18.5%.

RNA interference uses small interfering RNA molecules to guide the RNA-induced silencing complex toward a complementary messenger RNA sequence, suppressing production of a disease-associated protein ^{[1]National Center for Biotechnology Information - Small Interfering RNA (siRNA) Therapy. ncbi.nlm.nih.gov}. This mechanism makes the modality particularly relevant where pathogenic protein production originates in the liver and where conventional small molecules or antibodies cannot directly address the underlying target.

Commercial proof has moved the modality beyond its initial rare-disease position. Patisiran established the first U.S. regulatory precedent for an siRNA medicine in 2018, followed by givosiran, lumasiran, inclisiran, vutrisiran, nedosiran, and fitusiran across amyloidosis, metabolic disease, cardiovascular risk reduction, and hemophilia. The March 2025 approval of vutrisiran for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) was especially consequential because it extended RNAi into a larger cardiac population while preserving the liver-directed mechanism used in hereditary transthyretin-mediated amyloidosis (hATTR).

The present commercial base remains concentrated in liver-directed delivery. Patisiran uses a lipid nanoparticle formulation, whereas newer products predominantly use N-acetylgalactosamine (GalNAc) conjugation to engage the asialoglycoprotein receptor on hepatocytes ^{[2]Signal Transduction and Targeted Therapy - Landscape of Small Nucleic Acid Therapeutics. nature.com}. This distinction affects the cost and location of care: lipid nanoparticle delivery requires intravenous administration, while GalNAc conjugates support subcutaneous dosing at intervals ranging from monthly to twice yearly for approved products. The resulting shift toward lower-frequency subcutaneous administration is central to the market's growth profile.

Alnylam's 2024 combined net product revenue of USD 1,646 million, including USD 970 million from AMVUTTRA, illustrates that RNAi products can now generate large-scale specialty-pharma revenue rather than remain solely platform validation programs. Pipeline activity is also broadening. The American Society of Gene and Cell Therapy recorded 1,261 RNA therapies across development stages at the end of 2024, including 49 RNA trials initiated during the fourth quarter. Much of that opportunity remains contingent on solving delivery beyond hepatocytes, particularly for central nervous system, muscle, pulmonary, and oncology applications.

Near-term expansion is therefore likely to be led by approved hepatic indications and by inclisiran's progression through cardiovascular formularies. Extrahepatic programs carry substantial strategic value, but they should not be treated as a near-term substitute for liver-directed revenues. The same pharmacokinetic properties that make GalNAc conjugates commercially efficient in hepatocytes also limit their reach into tissues lacking the relevant uptake pathway. Companies that pair differentiated delivery technology with evidence generation and established specialty-market access are better positioned to capture the forecast opportunity than those relying on platform novelty alone.

Key Drivers

Increasing Prevalence of Genetic Disorders

RNAi is most readily applicable when disease biology identifies a liver-produced pathogenic protein or metabolic intermediate that can be reduced without compromising essential physiology. hATTR results from pathogenic variants in the TTR gene, with more than 130 variants described, and amyloid deposition can affect peripheral nerves and cardiac tissue ^{[3]Neurological Sciences - Hereditary Transthyretin Amyloidosis Overview. link.springer.com}. Better genetic testing and disease recognition are enlarging the diagnosed hATTR population, particularly in known endemic communities and in populations with variants associated with cardiomyopathy ^{[4]NCBI GeneReviews - Hereditary Transthyretin Amyloidosis. ncbi.nlm.nih.gov}.

The target pool extends beyond amyloidosis. Acute hepatic porphyria arises from inherited defects in heme biosynthesis, and givosiran reduces hepatic ALAS1 expression to lower accumulation of toxic aminolevulinic acid and porphobilinogen. Primary hyperoxaluria type 1 is another liver-origin metabolic disorder in which excess oxalate production can cause renal damage and systemic oxalosis. These diseases are commercially small, but they demonstrate a repeatable development logic: genetic diagnosis establishes a molecular target, liver delivery enables durable knockdown, and a measurable biochemical endpoint can support rare-disease development.

Hypercholesterolemia offers a different demand profile. Inclisiran reduces hepatic PCSK9 expression, thereby increasing available LDL receptors and lowering LDL cholesterol. Familial hypercholesterolemia alone affects approximately one in 250 people in its heterozygous form. The implication is significant: a modality validated in narrow orphan populations can address a substantially larger chronic-care population when payer access, prescriber confidence, and care-delivery capacity align.

Advancements in RNA Delivery Technologies

Lipid nanoparticles and GalNAc conjugates resolved different components of the RNAi delivery problem. Lipid nanoparticles protect siRNA from degradation and facilitate cytoplasmic release after cellular uptake; patisiran's APOLLO study demonstrated a median serum TTR reduction of 81%, compared with 3% for placebo ,. However, the intravenous route, infusion duration, and premedication requirements associated with patisiran created practical limitations for long-term treatment.

GalNAc conjugation shifted the commercial model by directing siRNA toward hepatocytes through receptor-mediated uptake after subcutaneous injection. Vutrisiran reduced serum TTR by a median of 94% at 18 months in HELIOS-A, demonstrating that lower-burden administration can retain deep target knockdown. Its subsequent ATTR-CM approval linked that delivery advantage to a cardiovascular outcomes program rather than solely to biomarker suppression.

The industry's next value inflection depends on selective extrahepatic delivery. Atalanta Therapeutics is developing di-siRNA technology for central nervous system programs, while Sirnaomics is pursuing polypeptide nanoparticle delivery in non-liver applications,. The NIH RNA-DASH initiative further signals public-sector support for technologies that can deliver RNA cargo to specific tissues beyond the liver. These platforms remain developmental, but successful tissue targeting would expand RNAi's indication set far more than incremental improvements to liver uptake alone.

Rising Investment in RNAi-Based Research

Strategic transactions show that delivery chemistry is being valued as a reusable asset rather than a product-specific feature. Novo Nordisk acquired Dicerna Pharmaceuticals in 2021, bringing the GalXC platform and nedosiran program into its research portfolio. Novartis commercialized inclisiran after acquiring The Medicines Company, creating a model in which a specialized RNAi asset is paired with a large cardiovascular franchise. Such transactions reduce development risk for platform companies while giving established manufacturers access to differentiated target-silencing capabilities.

Arrowhead Pharmaceuticals illustrates the partnership-driven approach. Its pipeline includes plozasiran, zodasiran, fazirsiran, and programs licensed to larger pharmaceutical partners, including olpasiran and GSK4532990. This structure can distribute late-stage development and commercialization costs while retaining exposure to milestones and royalties. It also suggests that competitive differentiation increasingly rests on target selection, delivery durability, and partnering discipline rather than on RNAi eligibility alone.

Computational approaches may improve early discovery efficiency. Reviews of siRNA design technologies describe machine-learning models that evaluate sequence, secondary structure, and off-target propensity before candidate synthesis,. These methods do not remove the need for biological validation or delivery optimization, but they can reduce unproductive screening iterations and focus laboratory resources on candidates with more favorable predicted activity.

Approval of RNAi Therapeutics for Chronic and Rare Diseases

Regulatory approvals have progressively widened the acceptable use cases for RNAi. The FDA approval of patisiran established a precedent for treating a severe inherited disorder through mRNA silencing, while later approvals supported the same modality across AHP, PH1, and dyslipidemia. The regulatory transition is commercially relevant because each approved product builds agency familiarity with oligonucleotide chemistry, delivery systems, safety monitoring, and surrogate biochemical endpoints.

Inclisiran's evolving U.S. label illustrates the route from specialist use to broader chronic-disease adoption. It was initially approved for adults with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia, expanded in 2023 to adults with elevated LDL-C and increased cardiovascular risk, and received a 2025 label update enabling first-line use. Wider eligibility does not automatically produce utilization, but it gives payers and primary-care systems a clearer basis for integrating twice-yearly administration into lipid-management pathways.

Fitusiran's March 2025 approval for hemophilia A or B with or without inhibitors broadened RNAi into hematology. By lowering antithrombin expression, the product rebalances hemostasis rather than replacing the missing coagulation factor, allowing one mechanism to serve patients across hemophilia types and inhibitor status. This expands the sector's clinical relevance but also brings a more complex safety and monitoring context than liver-targeted metabolic enzyme suppression.

Key Restraints

Challenges in Effective Delivery of RNAi Molecules

The liver remains RNAi's principal clinical success because its biology favors delivery. Hepatocytes are accessible from the circulation and express the asialoglycoprotein receptor exploited by GalNAc conjugates. In contrast, naked siRNA is vulnerable to enzymatic degradation, renal clearance, and uptake by phagocytic cells, while chemical modification alone cannot ensure deposition in the intended non-hepatic tissue.

This limitation narrows the commercial horizon of many pipeline claims. CNS programs must address the blood-brain barrier; pulmonary, muscular, renal, and tumor programs require tissue-selective uptake and enough cytoplasmic release to produce durable knockdown without unacceptable immune effects. Partial sequence complementarity can also produce unintended transcript suppression, and double-stranded RNA may activate innate immune pathways if chemistry and formulation are not appropriately designed. The technical challenge is therefore not simply transporting siRNA to an organ, but achieving reproducible intracellular delivery with a therapeutic index suitable for repeat administration.

High Cost of RNAi Therapeutics Development and Treatment

RNAi therapies face a cost structure shaped by specialized oligonucleotide chemistry, formulation development, sterile injectable manufacturing, and rare-disease clinical operations. A review of approved siRNA medicines identified estimated annual treatment costs exceeding USD 375,000 for patisiran and USD 500,000 for vutrisiran in the evaluated U.S. pricing context. These prices are more readily supported in progressive orphan diseases with major unmet need than in high-prevalence chronic conditions where payers compare RNAi products with lower-cost alternatives.

Clinical development can also be operationally intensive. The ENVISION trial of givosiran enrolled 94 patients at 36 sites in 18 countries, reflecting the global recruitment demands of very small rare-disease populations. Such trial structures increase per-patient cost and reinforce the advantage of companies with established rare-disease infrastructure. The cost issue is not only a launch-price question; it affects development prioritization, patient eligibility rules, and the ability of smaller platform developers to carry programs through confirmatory trials.

Access economics will determine how far RNAi moves from ultra-rare disease into broader populations. High annual costs can be accommodated where disease progression is severe and treatment alternatives are limited; they are harder to sustain when therapies compete with established oral agents, antibodies, or factor-based regimens. Developers that demonstrate reductions in care burden, acute events, or administration costs will have a stronger reimbursement case than those relying on molecular novelty. The commercial challenge is therefore to translate long-duration knockdown into payer-relevant outcomes, not merely to preserve biomarker efficacy.

RNA Interference Therapeutics Market Segment Analysis

By Indication

hATTR is the largest indication segment, valued at USD 1,499.6 million in 2025, representing 35.7% of the market, and is projected to reach USD 10,941.3 million by 2035 at an 18.2% CAGR. The segment is supported by established treatment infrastructure and by the transition from intravenous patisiran to quarterly subcutaneous vutrisiran. Both products reduce hepatic TTR production, but the GalNAc-conjugate regimen reduces the treatment burden associated with regular infusions. The continuing opportunity lies in improved diagnosis and care access, particularly for genetically defined populations and specialist centers familiar with amyloidosis management.

ATTR-CM is valued at USD 979.1 million in 2025 and is forecast to grow at a 19.2% CAGR to USD 7,753.2 million by 2035. The segment includes hereditary and wild-type disease, with the latter expanding the potential treatment population among older patients with cardiomyopathy. HELIOS-B demonstrated that vutrisiran reduced the composite of all-cause mortality and recurrent cardiovascular events in the overall population studied, supporting the March 2025 FDA approval. Its competitive position will depend on clinical adoption relative to TTR stabilizers, as well as the capacity of cardiology practices to identify ATTR-CM earlier in the diagnostic pathway.

AHP generated USD 307.6 million in 2025 and is projected to reach USD 2,271.4 million by 2035, at an 18.3% CAGR. Givosiran suppresses ALAS1, a key hepatic enzyme in the pathway producing the neurotoxic intermediates associated with acute attacks. In the ENVISION study, givosiran reduced annualized attack rates and intravenous hemin use compared with placebo. Commercial expansion is principally tied to finding eligible patients, maintaining reimbursement, and extending specialized metabolic care beyond established orphan-drug markets.

PH1 accounted for USD 210.8 million in 2025 and is projected to reach USD 1,636.2 million by 2035, expanding at 18.9%. Lumasiran and nedosiran intervene at different hepatic enzyme points in oxalate metabolism, creating therapeutic choice in a disease where early treatment can alter renal-risk management ^{[5]Springer Drugs - Nedosiran: First Approval. link.springer.com}. The segment's value is rooted in highly specialized diagnosis and treatment pathways rather than broad patient volume.

Hypercholesterolemia and dyslipidemia is the second-largest indication segment, at USD 1,194.5 million in 2025, or 28.4% of the total market, and is projected to reach USD 8,645.6 million by 2035 at an 18.1% CAGR. Inclisiran is the sole approved siRNA product in this segment and reduces PCSK9 synthesis through twice-yearly administration following its initiation schedule. Its scale potential is large, but its commercial conversion depends on formulary placement, care-provider workflow, and evidence expectations in a treatment category where statins and PCSK9 antibodies are already embedded.

Hemophilia A and B represents USD 10.2 million in 2025 and is projected to reach USD 87.2 million by 2035, recording the highest indication CAGR of 20.1%. Fitusiran lowers antithrombin to rebalance thrombin generation in hemophilia A and B, including patients with inhibitors. In ATLAS-INH, fitusiran prophylaxis reduced annualized bleeding rates relative to on-demand bypassing agents. The low 2025 base reflects its recent launch, while the forecast captures the potential expansion of payer coverage and treatment-center experience.

FCS is valued at USD 3.0 million in 2025 and is projected to reach USD 27.0 million by 2035, at a 19.6% CAGR. Plozasiran targets APOC3 and, in the PALISADE study, reduced triglycerides and acute pancreatitis events in persistent chylomicronemia ^{[6]New England Journal of Medicine - Plozasiran for Managing Persistent Chylomicronemia. nejm.org}. Its importance extends beyond immediate revenue because it would further validate RNAi in severe lipid disorders where the clinical burden is driven by pancreatitis risk rather than LDL cholesterol.

By Route of Administration

Subcutaneous administration accounts for USD 4,032.0 million in 2025, representing 95.9% of global revenue, and is projected to reach USD 31,054.4 million by 2035 at an 18.6% CAGR. GalNAc conjugation supports this dominance by enabling targeted liver uptake without infusion infrastructure. The route accommodates monthly, quarterly, and twice-yearly regimens across rare disease and cardiovascular care, making it compatible with maintenance treatment in specialty centers and, increasingly, outpatient clinics.

Intravenous administration represents USD 172.8 million in 2025 and is projected to reach USD 307.4 million by 2035, at an 11.5% CAGR. This segment is centered on patisiran, which requires an intravenous infusion and associated premedication. Its slower growth reflects substitution by subcutaneous vutrisiran, not a loss of clinical relevance for the foundational lipid nanoparticle platform. Patisiran continues to demonstrate how formulation can enable potent RNAi activity, while its care burden explains why newer products increasingly favor conjugate-based delivery.

By End Use

Hospitals generate USD 2,114.0 million in 2025, or 50.3% of market revenue, and are projected to reach USD 15,846.3 million by 2035 at an 18.5% CAGR. They remain central to diagnosis, treatment initiation, infusion delivery, and multidisciplinary management in amyloidosis, porphyria, pediatric metabolic disease, and hemophilia. Hospital involvement is especially material where safety monitoring or specialist coordination is required.

Specialty treatment centers account for USD 1,286.4 million in 2025 and are forecast to reach USD 9,985.7 million by 2035, at an 18.9% CAGR. These settings consolidate expertise in rare metabolic diseases, cardiomyopathy, hemophilia, nephrology, and lipid disorders. Their faster growth reflects the fit between infrequent subcutaneous administration and structured follow-up, laboratory monitoring, and patient-support processes.

Clinics contribute USD 804.4 million in 2025 and are projected to reach USD 5,529.9 million by 2035 at a 17.5% CAGR. Their role is most developed in hypercholesterolemia, where inclisiran can be administered within cardiology or primary-care workflows. The opportunity is meaningful, but clinic adoption depends on reimbursement mechanisms, site-of-care economics, and operational integration rather than on product efficacy alone.

The 95.9% subcutaneous share is not merely an administration preference. It reflects a market selection mechanism favoring products that can deliver durable hepatic knockdown without recurring infusion-center use. This route is likely to reinforce specialty-center growth and permit selective movement toward clinic-based delivery in lipid management. By contrast, the intravenous segment's slower forecast makes clear that delivery convenience is becoming a competitive attribute with direct consequences for site of care, treatment persistence, and resource use.

RNA Interference Therapeutics Market Regional Analysis

North America

North America is valued at USD 3,027.4 million in 2025, representing 72.0% of the global market, and is projected to reach USD 22,784.6 million by 2035 at an 18.6% CAGR. The United States accounts for USD 2,885.9 million, or 95.3% of the regional market, while Canada contributes USD 141.5 million. U.S. market value increased from USD 575.9M in 2022 to USD 898.7M in 2023, USD 1.4B in 2024, and USD 2.9B in 2025.

The region benefits from early FDA approvals, established rare-disease centers, and specialty-pharmacy and payer systems capable of managing high-cost biologics. The ATTR-CM approval for vutrisiran is particularly important in the United States because diagnosis and treatment are concentrated in cardiology, amyloidosis, and neuromuscular referral networks. However, broad chronic-care uptake, especially for inclisiran, remains influenced by formulary requirements and competition with established lipid-lowering therapies.

Europe

Europe is valued at USD 714.8 million in 2025 and is projected to reach USD 5,278.4 million by 2035, expanding at an 18.3% CAGR. Germany, the UK, France, Spain, Italy, and the Netherlands form the principal covered markets. Centralized European authorization can provide a common regulatory basis for RNAi medicines, but national health technology assessment and pricing decisions determine the pace of practical access.

The region has a clinically distinctive ATTR opportunity because hATTR has recognized endemic clusters in Portugal, Sweden, and other European locations. The EMA has authorized both Onpattro and Amvuttra, while country-level reimbursement processes determine whether these approvals translate into broad treatment access. This makes European growth more dependent on time to reimbursement and negotiated value assessment than on regulatory authorization alone.

Asia Pacific

Asia Pacific represents USD 294.3 million in 2025 and is projected to reach USD 2,250.8 million by 2035, recording the highest regional CAGR of 18.8%. The regional scope includes China, India, Japan, Australia, and South Korea. Japan has established experience with hereditary ATTR amyloidosis and is one of the historically recognized endemic markets for the disease. This provides a specialized clinical base for amyloidosis therapies.

The region's longer-term potential also derives from diagnostic expansion, regulatory modernization, and local RNAi platform development. OliX Pharmaceuticals is developing asymmetric siRNA technologies for local and liver-directed applications, illustrating growing regional participation beyond medicine importation ^{[7]Korea Biomedical Review - OliX Pharmaceuticals Programs and Platform Developments. koreabiomed.com}. China's scale and evolving rare-disease infrastructure may support growth, although reimbursement and diagnostic access remain uneven across the region.

Rest of World

Rest of World is valued at USD 168.2 million in 2025 and is forecast to reach USD 1,048.0 million by 2035, at a 16.3% CAGR. The region includes Latin America, the Middle East, Africa, and other markets outside the principal North American, European, and Asia Pacific groupings. Growth is moderated by slower regulatory sequencing, constrained reimbursement capacity for ultra-high-cost treatments, and limited specialist referral infrastructure.

Rare genetic and metabolic disorders are clinically present across these markets, but market conversion requires more than disease prevalence. Genetic testing, disease registries, specialist centers, supply-chain capability, and public or private funding mechanisms must develop together before high-cost RNAi medicines can achieve meaningful penetration. As a result, the region is more likely to follow launches in leading markets than to establish independent early-adoption patterns.

Europe has the clinical capability to remain the second-largest region, but its revenue conversion is governed by country-specific value assessment and negotiated access. Asia Pacific's 18.8% CAGR is supported by Japan's established amyloidosis experience and by broader improvements in diagnostic and biotechnology capacity, yet its share remains constrained by uneven payment systems. The regional split therefore measures the maturity of specialty-care and financing infrastructure as much as it measures disease burden.

RNA Interference Therapeutics Market Share & Competitive Landscape

Alnylam Pharmaceuticals remains the leading commercial RNAi company. Its approved portfolio includes ONPATTRO, GIVLAARI, OXLUMO, and AMVUTTRA across hATTR, AHP, PH1, and ATTR-CM. The company reported USD 1,646 million in combined net product revenue in 2024, including USD 970 million from AMVUTTRA, demonstrating that its GalNAc platform and rare-disease commercialization capabilities have become substantial competitive barriers.

Novartis participates through LEQVIO, the PCSK9-targeting siRNA product positioned in cardiovascular risk reduction. Its advantage is commercial scale in cardiology and broad experience in population-based access models, including UK commissioning arrangements. The strategic question for Novartis is whether it can convert low-frequency administration into formulary preference in a market that remains highly sensitive to comparative cost and outcomes evidence.

Novo Nordisk entered RNAi through its acquisition of Dicerna Pharmaceuticals and markets RIVFLOZA for PH1. The acquisition gave Novo Nordisk an independent GalNAc-conjugate platform that can support future metabolic and cardiovascular programs. Sanofi's RNAi presence is centered on QFITLIA, the antithrombin-directed therapy approved for hemophilia A and B, where the company's hematology infrastructure may support uptake in treatment centers.

Arrowhead Pharmaceuticals has one of the broadest development portfolios among RNAi-focused companies. Its TRiM platform supports programs in lipid disease, liver disease, metabolic disorders, and selected extrahepatic targets; plozasiran is its most visible late-stage program in FCS. Arrowhead's licensing approach can reduce capital requirements while retaining development optionality, although partner priorities may influence the timing of commercial progression.

Silence Therapeutics is advancing the mRNAi GOLD platform, including zerlasiran for elevated lipoprotein(a) and divesiran for polycythemia vera ^{[8]Silence Therapeutics - Full Year 2024 Financial Results and Business Update. silence-therapeutics.com}. The Phase 2 ALPACAR-360 study reported sustained lipoprotein(a) lowering through 48 weeks, supporting its cardiovascular-development rationale ^{[9]Silence Therapeutics - Positive Topline 48-Week Data From the Phase 2 ALPACAR-360 Study of Zerlasiran. silence-therapeutics.com}. Sirnaomics differentiates through polypeptide nanoparticle technology designed for extrahepatic and topical delivery, with STP705 and STP707 targeting TGF-b1 and COX-2 in dermatology and oncology programs.

Arbutus Biopharma is developing imdusiran for chronic hepatitis B, where lowering hepatitis B surface antigen may contribute to combination approaches aimed at functional cure. Its lipid nanoparticle intellectual property also remains relevant to the wider nucleic-acid delivery landscape. Benitec Biopharma is developing DNA-directed RNA interference through BB-301 for oculopharyngeal muscular dystrophy, using a "silence and replace" approach intended to provide durable target suppression after administration.

OliX Pharmaceuticals is developing cell-penetrating asymmetric siRNA and GalNAc-conjugated asiRNA platforms, including OLX104C for androgenetic alopecia and partnered liver-targeted programs. Atalanta Therapeutics is pursuing di-siRNA technology for central nervous system indications, including Huntington's disease and KCNT1-related epilepsy. These companies remain pre-commercial, but their platforms address the strategic constraint shared by the sector: extending RNAi beyond hepatocytes without sacrificing safety or durable target engagement.

Recent Industry Developments

• March 2025 - AMVUTTRA approval for ATTR-CM: The FDA approved Alnylam's AMVUTTRA for cardiomyopathy of wild-type or hereditary ATTR-CM. The decision followed HELIOS-B, which showed a reduction in all-cause mortality and recurrent cardiovascular events in the studied population.

• March 2025 - QFITLIA approval for hemophilia: The FDA approved Sanofi's QFITLIA for routine prophylaxis to prevent or reduce bleeding episodes in hemophilia A or B, with or without factor VIII or IX inhibitors. The approval introduced an antithrombin-lowering RNAi mechanism into hemophilia management.